| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68001-0546-41 | 68001-0546 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Sep 1, 2023 | In Use | |
| 63323-0137-20 | 63323-0137 | Bleomycin Sulfate | Bleomycin | 30.0 [USP'U]/1 | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intramuscular, Intrapleural, Intravenous, Subcutaneous | Feb 13, 2009 | In Use | |
| 59651-0545-30 | 59651-0545 | DASATINIB | DASATINIB | 80.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 22, 2025 | In Use | |
| 67386-0811-55 | 67386-0811 | Dactinomycin | Cosmegen | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | Intravenous | Dec 10, 1964 | Apr 23, 2013 | No Longer Used | |
| 31722-0358-20 | 31722-0358 | Oxaliplatin | Oxaliplatin | 100.0 mg/20mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan 27, 2025 | In Use | |
| 63323-0103-51 | 63323-0103 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sep 5, 2000 | In Use | |
| 00245-0825-30 | 00245-0825 | Everolimus | TORPENZ | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 24, 2024 | In Use | |
| 45963-0614-56 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug 11, 2018 | In Use | |
| 00013-2201-01 | 00013-2201 | Idarubicin Hydrochloride | Idamycin PFS | Chemotherapy | Antitumor Antibiotic | Anthracycline | Feb 17, 1997 | Jun 1, 2010 | No Longer Used | ||
| 00069-3030-20 | 00069-3030 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Dec 23, 1987 | Sep 30, 2025 | In Use |
| 81927-0375-01 | 81927-0375 | Nelarabine | Nelarabine | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 31, 2025 | In Use | |
| 62332-0751-50 | 62332-0751 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Mar 3, 2023 | In Use | |
| 00310-0625-28 | 00310-0625 | SELUMETINIB | KOSELUGO | 25.0 mg/1 | Chemotherapy | MEK Inhibitor | MEK 1/2 | Oral | Jun 11, 2021 | In Use | |
| 62332-0813-50 | 62332-0813 | Nelarabine | NELARABINE | 5.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Aug 1, 2024 | In Use | |
| 43975-0255-14 | 43975-0255 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jul 13, 2016 | In Use | |
| 47335-0891-21 | 47335-0891 | Temozolomide | Temozolomide | 20.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 83831-0183-04 | 83831-0183 | Bendamustine hydrochloride | BENDAMUSTINE HYDROCHLORIDE | 100.0 mg/4mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | May 29, 2026 | In Use | |
| 00069-0227-01 | 00069-0227 | Lorlatinib | Lorbrena | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK/ROS1 | Oral | Nov 19, 2018 | In Use | |
| 49884-0922-02 | 49884-0922 | Mercaptopurine | Mercaptopurine | 50.0 mg/1 | Chemotherapy | Antimetabolite | Purine Analog | Oral | Feb 11, 2004 | Apr 30, 2018 | No Longer Used |
| 62856-0714-05 | 62856-0714 | Lenvatinib | Lenvima | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET | Oral | Feb 13, 2015 | In Use | ||
| 71335-2221-07 | 71335-2221 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Aug 15, 2023 | In Use | |
| 72237-0101-07 | 72237-0101 | Selinexor | XPOVIO | 20.0 mg/1 | Chemotherapy | Enzyme Inhibitor | XPO1 | Oral | Jun 22, 2020 | In Use | |
| 59923-0714-02 | 59923-0714 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Mar 1, 2019 | In Use | |
| 00069-4030-01 | 00069-4030 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Mar 5, 2013 | Aug 31, 2021 | No Longer Used |
| 58468-7860-03 | 58468-7860 | Vandetanib | CAPRELSA | 300.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Oral | Jun 24, 2022 | In Use |
Found 12611 results — Export these results
Home